Paradigm Diagnostics Raises $3.5M of Planned $7M Series B Financing | GenomeWeb

NEW YORK (GenomeWeb) – Paradigm Diagnostics today announced the first closing of what it expects to be a $7 million Series B financing to support the rapid commercial expansion of its PCDx tumor sequencing test.

The first tranche of the funding round, which raised $3.5 million, was led by Mesa Verde Venture Partners. Mesa Verde managing director Carey Ng also joined Paradigm's board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
23
Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.